MX2009002936A - Biomarcadores de la modulacion de objetivo, eficacia, diagnostico, y/o pronostico para los inhibidores de raf. - Google Patents
Biomarcadores de la modulacion de objetivo, eficacia, diagnostico, y/o pronostico para los inhibidores de raf.Info
- Publication number
- MX2009002936A MX2009002936A MX2009002936A MX2009002936A MX2009002936A MX 2009002936 A MX2009002936 A MX 2009002936A MX 2009002936 A MX2009002936 A MX 2009002936A MX 2009002936 A MX2009002936 A MX 2009002936A MX 2009002936 A MX2009002936 A MX 2009002936A
- Authority
- MX
- Mexico
- Prior art keywords
- biomarkers
- prognosis
- efficacy
- diagnosis
- target modulation
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
En la presente se enseñan métodos para utilizar biomarcadores con el fin de identificar a los pacientes para el tratamiento o para monitorear su respuesta al tratamiento. Se miden las alteraciones en los niveles de la expresión genética de los biomarcadores, en particular en respuesta a la inhibición de la cinasa RAF, y de conformidad con lo mismo, se pueden hacer identificaciones o ajustes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84560106P | 2006-09-19 | 2006-09-19 | |
PCT/US2007/078946 WO2008082730A2 (en) | 2006-09-19 | 2007-09-19 | Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009002936A true MX2009002936A (es) | 2009-04-01 |
Family
ID=39445772
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009002936A MX2009002936A (es) | 2006-09-19 | 2007-09-19 | Biomarcadores de la modulacion de objetivo, eficacia, diagnostico, y/o pronostico para los inhibidores de raf. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20100004253A1 (es) |
EP (1) | EP2074226A2 (es) |
JP (2) | JP2010504530A (es) |
KR (1) | KR20090071603A (es) |
CN (1) | CN101541977A (es) |
AU (1) | AU2007340265B2 (es) |
BR (1) | BRPI0716944A2 (es) |
CA (1) | CA2662508A1 (es) |
IL (1) | IL197450A0 (es) |
MX (1) | MX2009002936A (es) |
RU (1) | RU2009114745A (es) |
SG (1) | SG174826A1 (es) |
WO (1) | WO2008082730A2 (es) |
Families Citing this family (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
IL282783B2 (en) | 2006-05-18 | 2023-09-01 | Caris Mpi Inc | A system and method for determining a personalized medical intervention for a disease stage |
CA2728674A1 (en) * | 2008-06-26 | 2009-12-30 | Dana-Farber Cancer Institute, Inc. | Signatures and determinants associated with metastasis methods of use thereof |
US8583380B2 (en) | 2008-09-05 | 2013-11-12 | Aueon, Inc. | Methods for stratifying and annotating cancer drug treatment options |
NZ592338A (en) | 2008-09-26 | 2012-11-30 | Oncomed Pharm Inc | Frizzled-binding agents and uses thereof |
BRPI0921043A2 (pt) | 2008-11-12 | 2018-08-07 | Caris Life Sciences Luxembourg Holdings | métodos e sistemas para usar exossomas para determinar fenótipos |
US20120041274A1 (en) * | 2010-01-07 | 2012-02-16 | Myriad Genetics, Incorporated | Cancer biomarkers |
MY156210A (en) | 2009-11-18 | 2016-01-29 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt拮抗劑及治療和篩選方法 |
JP5808349B2 (ja) | 2010-03-01 | 2015-11-10 | カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー | セラノーシスのためのバイオマーカー |
WO2011127219A1 (en) | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings | Circulating biomarkers for disease |
US8709419B2 (en) * | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
US20120045433A1 (en) * | 2010-08-17 | 2012-02-23 | Kapil Dhingra | Combination therapy |
CA2810931C (en) | 2010-09-24 | 2018-04-17 | The Board Of Trustees Of The Leland Stanford Junior University | Direct capture, amplification and sequencing of target dna using immobilized primers |
EP2444503B1 (en) * | 2010-10-20 | 2016-03-02 | Université Joseph Fourier | Use of specific genes for the prognosis of lung cancer and the corresponding progonosis method |
TW201300423A (zh) * | 2010-10-21 | 2013-01-01 | Oncotherapy Science Inc | C18orf54胜肽與含此胜肽之疫苗 |
US9295669B2 (en) | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
MX349011B (es) * | 2011-06-02 | 2017-07-05 | Novartis Ag | Biomarcadores para terapia de inhibidor de hedgehog. |
CA2838086A1 (en) | 2011-06-02 | 2012-12-06 | Almac Diagnostics Limited | Molecular diagnostic test for cancer |
US20140302042A1 (en) * | 2011-07-01 | 2014-10-09 | Dana-Farber Cancer Institute, Inc. | Methods of predicting prognosis in cancer |
WO2013055911A1 (en) | 2011-10-14 | 2013-04-18 | Dana-Farber Cancer Institute, Inc. | Znf365/zfp365 biomarker predictive of anti-cancer response |
JP2015502958A (ja) * | 2011-12-09 | 2015-01-29 | オンコメッド ファーマシューティカルズ インコーポレイテッド | がんの処置のための併用療法 |
JP6192123B2 (ja) * | 2012-01-09 | 2017-09-06 | スージョウ マイクロダイアグ バイオメディスン カンパニー リミテッド | 乳癌の予測および診断のためのバイオマーカー |
US9428813B2 (en) | 2012-03-26 | 2016-08-30 | The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services | DNA methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms |
WO2013167153A1 (en) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
PT2884979T (pt) | 2012-08-17 | 2019-09-04 | Hoffmann La Roche | Terapêuticas combinadas para o melanoma, compreendendo a administração de cobimetinib e vemurafinib |
TWI601725B (zh) * | 2012-08-27 | 2017-10-11 | 加拓科學公司 | 取代的氮雜吲哚化合物及其鹽、組合物和用途 |
US20150252428A1 (en) * | 2012-10-03 | 2015-09-10 | Exosome Diagnostics, Inc. | Use of microvesicles in diagnosis, prognosis, and treatment of medical diseases and conditions |
WO2014087156A1 (en) | 2012-12-03 | 2014-06-12 | Almac Diagnostics Limited | Molecular diagnostic test for cancer |
CA2899353A1 (en) | 2013-02-04 | 2014-08-07 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a wnt pathway inhibitor |
US10023916B2 (en) * | 2013-04-15 | 2018-07-17 | Regeneron Pharmaceuticals, Inc. | Markers of tumor cell response to anti-cancer therapy |
CN103941016B (zh) * | 2013-05-07 | 2016-04-27 | 上海良润生物医药科技有限公司 | 半胱氨酸蛋白酶抑制剂sn与癌胚抗原的联合应用 |
DK2997376T3 (da) * | 2013-05-13 | 2020-09-21 | Roussy Inst Gustave | Prognose og prædiktive biomarkører og biologiske anvendelser deraf |
US11136625B2 (en) | 2013-08-28 | 2021-10-05 | Crown Bioscience, Inc. (Taicang) | Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same |
EP3074536B1 (en) | 2013-11-25 | 2019-06-19 | Children's Hospital Medical Center | Temporal pediatric sepsis biomarker risk model |
CA3206268A1 (en) * | 2013-12-06 | 2015-06-11 | Celgene Corporation | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers |
MX2016007369A (es) * | 2013-12-12 | 2016-09-08 | Stemcentrx Inc | Nuevos anticuerpos anti-dpep3 y metodos de uso. |
US10545144B2 (en) | 2013-12-31 | 2020-01-28 | Yeda Research And Development Co., Ltd. | Diagnosis of systemic lupus erythematosus using oligonucleotides antigens |
GB201409479D0 (en) | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Molecular diagnostic test for cancer |
CN111808957A (zh) | 2014-04-04 | 2020-10-23 | 中美冠科生物技术(太仓)有限公司 | 用于确定对mek/erk抑制剂的应答性的方法 |
GB201408100D0 (en) * | 2014-05-07 | 2014-06-18 | Sec Dep For Health The | Detection method |
WO2016011065A1 (en) * | 2014-07-15 | 2016-01-21 | Salk Institute For Biolofical Studies | Detecting dixdc1 (dix domain-containing protein 1) expression to determine if a tumor will respond to fak and src kinase inhibitors |
EP3207151A4 (en) * | 2014-10-13 | 2018-07-04 | Celgene Corporation | Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
CN104502603B (zh) * | 2014-12-03 | 2016-04-06 | 上海交通大学医学院附属上海儿童医学中心 | Myo1d作为诊断动脉导管闭合或开放的标志物 |
CN105986023B (zh) * | 2015-02-17 | 2021-01-05 | 上海交通大学医学院附属上海儿童医学中心 | 急性淋巴细胞白血病耐药复发相关突变基因及其应用 |
WO2016131420A1 (zh) | 2015-02-17 | 2016-08-25 | 上海交通大学医学院附属上海儿童医学中心 | 急性淋巴细胞白血病耐药复发相关突变基因及其应用 |
CN107533058A (zh) | 2015-03-01 | 2018-01-02 | 免疫阵列有限公司 | 使用蛋白、肽和寡核苷酸抗原诊断系统性红斑狼疮 |
CN105063183A (zh) * | 2015-07-22 | 2015-11-18 | 浙江理工大学 | 泛素化途径相关基因在作为用于预测乳腺癌新辅助化疗疗效的生物标记物的应用 |
WO2017025954A1 (en) * | 2015-08-09 | 2017-02-16 | Immunarray Ltd | Methods for determining the risk of a systemic lupus erythematosus (sle) patient to develop neuropsychiatric syndromes |
WO2017027672A1 (en) * | 2015-08-12 | 2017-02-16 | Celgene Corporation | Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
CN105126080A (zh) * | 2015-09-29 | 2015-12-09 | 武汉大学 | 锌指蛋白436(znf436)在治疗心肌肥厚中的应用 |
CN105671158B (zh) * | 2016-02-29 | 2019-01-18 | 北京泱深生物信息技术有限公司 | Fam63b基因在制备诊治子宫肌瘤的产品中的用途 |
JP2019518426A (ja) * | 2016-04-15 | 2019-07-04 | ジェネンテック, インコーポレイテッド | がんの診断及び治療方法 |
CN105695617A (zh) * | 2016-04-22 | 2016-06-22 | 王冬国 | 乳头状癌的肿瘤标志物及其应用 |
MA45496A (fr) * | 2016-06-17 | 2019-04-24 | Hoffmann La Roche | Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b |
JP2019528279A (ja) * | 2016-08-17 | 2019-10-10 | アイカーン スクール オブ メディシン アット マウント サイナイ | キナーゼ阻害物質化合物、組成物、及びがんの治療方法 |
CN108300783A (zh) * | 2017-01-11 | 2018-07-20 | 上海易毕恩基因科技有限公司 | 用于筛选肠癌和/或胃癌的基因标志物的方法、用该方法筛选的基因标志物及其用途 |
AU2018209164B2 (en) | 2017-01-17 | 2021-11-04 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
CN110914457A (zh) * | 2017-03-15 | 2020-03-24 | 卫材研究发展管理有限公司 | 剪接体突变及其用途 |
CN109081866B (zh) * | 2017-06-13 | 2021-07-16 | 北京大学 | 癌症中的t细胞亚群及其特征基因 |
CN113684275B (zh) * | 2017-06-22 | 2024-02-27 | 北海康成(北京)医药科技有限公司 | 预测食管癌对抗erbb3抗体治疗的应答的方法和试剂盒 |
UA126931C2 (uk) | 2017-10-16 | 2023-02-22 | Ф. Хоффманн-Ля Рош Аг | МОЛЕКУЛИ НУКЛЕЇНОВИХ КИСЛОТ ДЛЯ ЗМЕНШЕННЯ РІВНЯ мРНК PAPD5 І PAPD7 ДЛЯ ЛІКУВАННЯ ІНФЕКЦІЙНОГО ГЕПАТИТУ B |
CN109825508A (zh) * | 2017-11-23 | 2019-05-31 | 深圳市第三人民医院 | 一种用来评估艾滋病合并结核感染的生物标记物 |
CN109870576B (zh) * | 2017-12-05 | 2021-08-10 | 中国科学院大连化学物理研究所 | Usp10蛋白的定量检测在原发性肝癌预后判断试剂盒中的应用 |
US12054558B2 (en) * | 2018-05-23 | 2024-08-06 | The Jackson Laboratory | Anti-NGly-1 antibodies and methods of use |
CN108707628B (zh) * | 2018-05-28 | 2021-11-23 | 上海海洋大学 | 斑马鱼notch2基因突变体的制备方法 |
CN108753834B (zh) * | 2018-05-28 | 2021-11-23 | 上海海洋大学 | ddx27基因缺失斑马鱼突变体的制备方法 |
CN108676867B (zh) * | 2018-06-06 | 2020-06-09 | 青岛泱深生物医药有限公司 | 诊治子痫前期的vwce基因及其应用 |
CN108624678B (zh) * | 2018-06-26 | 2020-07-17 | 青岛泱深生物医药有限公司 | 一种用于子痫前期诊治的生物标志物 |
CN108841960B (zh) * | 2018-07-12 | 2022-02-01 | 吉林大学 | 一种结肠腺癌易感性预测试剂盒及系统 |
CN109468320A (zh) * | 2018-11-13 | 2019-03-15 | 复旦大学附属中山医院 | 一种环状rna及其在肝癌诊断中的应用 |
CN111467493A (zh) * | 2019-01-23 | 2020-07-31 | 首都师范大学 | 人rev3l蛋白切割抑制剂及其应用 |
CN111896740A (zh) * | 2019-05-06 | 2020-11-06 | 山东大学 | 诊断或预测生育缺陷的方法和试剂盒 |
JP2022543722A (ja) * | 2019-08-16 | 2022-10-14 | センター フォー エクセレンス イン ブレイン サイエンス アンド インテリジェンス テクノロジー,チャイニーズ アカデミー オブ サイエンシーズ | 機能的ニューロン死に関連する神経系疾患の予防および/または治療におけるPtbp1阻害剤の使用 |
CN110551819B (zh) * | 2019-08-23 | 2023-05-16 | 伯克利南京医学研究有限责任公司 | 一组卵巢癌预后相关基因的应用 |
CN110408706B (zh) * | 2019-08-30 | 2023-04-11 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | 一种评估鼻咽癌复发的生物标志物及其应用 |
CN110643571B (zh) * | 2019-10-22 | 2021-07-27 | 康妍葆(北京)干细胞科技有限公司 | 人角蛋白6a在干细胞培养中的应用及产品 |
CN110819714B (zh) * | 2019-11-22 | 2023-01-10 | 南方医科大学深圳医院 | 一种抑癌基因及其应用 |
TW202134239A (zh) * | 2019-11-27 | 2021-09-16 | 大陸商蘇州亞盛藥業有限公司 | 用於預測靶向細胞凋亡途徑的化合物的抗癌功效的方法和組合物 |
CN111781358A (zh) * | 2020-07-13 | 2020-10-16 | 张瑜 | Xab2蛋白作为卵巢癌预后和/或预测铂类耐药标志物 |
CN113943798B (zh) * | 2020-07-16 | 2023-10-27 | 中国农业大学 | 一种circ RNA作为肝细胞癌诊断标志物及治疗靶点的应用 |
CN112816708B (zh) * | 2021-02-02 | 2022-05-31 | 中南大学湘雅二医院 | 一种预测食管鳞癌患者对化疗药物敏感性的蛋白指标及应用 |
CN112691195B (zh) * | 2021-02-02 | 2023-03-14 | 黑龙江省科学院高技术研究院 | Prpf8表达抑制剂在制备治疗肺癌的药物中的应用 |
CN112816711B (zh) * | 2021-03-17 | 2024-04-19 | 中国医科大学附属盛京医院 | 用于神经管畸形、先天性心脏病和唇腭裂胎儿产前无创诊断的分子标志物及其应用 |
CN113373220A (zh) * | 2021-05-08 | 2021-09-10 | 首都医科大学 | 与非小细胞肺癌预后相关的标志分子 |
CN113416739B (zh) * | 2021-06-24 | 2022-04-19 | 黑龙江八一农垦大学 | 鲁氏酵母菌基因在提高微生物产hdmf的产量中的应用 |
CN113667749A (zh) * | 2021-08-03 | 2021-11-19 | 广东省人民医院 | 四个关键基因组合评估乳腺癌风险的诊断试剂盒 |
CN113866424A (zh) * | 2021-09-14 | 2021-12-31 | 哈尔滨医科大学 | 碳酸酐酶1和酸性鞘磷脂酶样磷酸二酯酶3a作为分子标志物在结直肠癌诊断中的应用 |
CN113897437B (zh) * | 2021-11-30 | 2024-06-04 | 深圳市人民医院 | 检测样本中标志物表达水平的试剂在制备用于诊断乳腺癌的试剂盒中的应用 |
CN114592059A (zh) * | 2022-01-11 | 2022-06-07 | 南方医科大学南方医院 | 一种评估5-fu治疗敏感性/耐药性的试剂盒 |
WO2023174381A1 (zh) * | 2022-03-16 | 2023-09-21 | 南京施江医药科技有限公司 | 一种含氮杂环类化合物及其用途 |
CN114672551B (zh) * | 2022-05-17 | 2023-03-31 | 中国医科大学附属第一医院 | Mat2a和mat2b作为检测或治疗良性前列腺增生的药物靶点的应用 |
CN115948529A (zh) * | 2022-08-01 | 2023-04-11 | 湖南家辉生物技术有限公司 | 一种Cornelia de Lange综合征1型的致病基因、引物对及其应用 |
WO2024107924A2 (en) * | 2022-11-17 | 2024-05-23 | Board Of Regents, The University Of Texas System | A blood-based lipid biomarker panel for personalized risk assessment of breast cancer |
CN115948537B (zh) * | 2022-12-19 | 2024-04-09 | 湖南家辉生物技术有限公司 | 一种基因chst3复合杂合突变的应用及检测试剂和应用 |
CN116287253B (zh) * | 2023-02-22 | 2024-06-28 | 武汉科技大学 | 一种肺癌分子标志物及其应用 |
CN117257919A (zh) * | 2023-11-10 | 2023-12-22 | 南通大学附属医院 | Tbc1d15在筛选或制备保护肝脏的药物中的应用 |
CN117821469B (zh) * | 2023-11-22 | 2024-08-02 | 扬州大学 | 一种鸡trim45截短体重组蛋白或其多克隆抗体的应用 |
CN118045083B (zh) * | 2024-04-15 | 2024-06-18 | 哈尔滨医科大学 | L-脯氨酸在制备防治非酒精性脂肪肝病药物中的新用途 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5604260A (en) * | 1992-12-11 | 1997-02-18 | Merck Frosst Canada Inc. | 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 |
US20030119769A1 (en) * | 1994-05-31 | 2003-06-26 | Monia Brett P | Antisense oligonucleotide modulation of raf gene expression |
US6358932B1 (en) * | 1994-05-31 | 2002-03-19 | Isis Pharmaceticals, Inc. | Antisense oligonucleotide inhibition of raf gene expression |
US6391636B1 (en) * | 1994-05-31 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
EP0910401A1 (en) * | 1996-05-23 | 1999-04-28 | Applied Research Systems ARS Holdings N.V. | Compounds that inhibit the binding of raf-1 or 14-3-3 proteins to the beta chain of il-2 receptor, and pharmaceutical compositions containing same |
AR012634A1 (es) * | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
US6187799B1 (en) * | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
GB9716557D0 (en) * | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
RU2319693C9 (ru) * | 1999-01-13 | 2008-08-20 | Байер Копэрейшн | Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты) |
US6610484B1 (en) * | 1999-01-26 | 2003-08-26 | Cytyc Health Corporation | Identifying material from a breast duct |
US20040018570A1 (en) * | 1999-09-01 | 2004-01-29 | Brown University | Kinase inhibitors and methods of use in screening assays and modulation of cell proliferation and growth |
AU2003222221A1 (en) * | 2002-02-15 | 2004-10-25 | The General Hospital Corporation | Map-kinase inhibitors as regulators of tumour-associated antigen expression |
US20040224302A1 (en) * | 2002-07-16 | 2004-11-11 | Thomas Jessel | Systems and methods for screening for modulators of neural differentiation |
CA2499852A1 (en) * | 2002-09-30 | 2004-04-08 | Bayer Pharmaceuticals Corporation | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
EP2295602B1 (en) * | 2005-07-27 | 2012-07-11 | Oncotherapy Science, Inc. | Method of prognosing cancers |
TW200804345A (en) * | 2005-08-30 | 2008-01-16 | Novartis Ag | Substituted benzimidazoles and methods of preparation |
-
2007
- 2007-09-19 CN CNA2007800426892A patent/CN101541977A/zh active Pending
- 2007-09-19 BR BRPI0716944-2A2A patent/BRPI0716944A2/pt not_active IP Right Cessation
- 2007-09-19 WO PCT/US2007/078946 patent/WO2008082730A2/en active Application Filing
- 2007-09-19 EP EP07872305A patent/EP2074226A2/en not_active Withdrawn
- 2007-09-19 KR KR1020097007973A patent/KR20090071603A/ko not_active Application Discontinuation
- 2007-09-19 MX MX2009002936A patent/MX2009002936A/es active IP Right Grant
- 2007-09-19 RU RU2009114745/10A patent/RU2009114745A/ru not_active Application Discontinuation
- 2007-09-19 SG SG2011067519A patent/SG174826A1/en unknown
- 2007-09-19 AU AU2007340265A patent/AU2007340265B2/en not_active Ceased
- 2007-09-19 JP JP2009529376A patent/JP2010504530A/ja active Pending
- 2007-09-19 CA CA002662508A patent/CA2662508A1/en not_active Abandoned
- 2007-09-19 US US12/441,888 patent/US20100004253A1/en not_active Abandoned
-
2009
- 2009-03-05 IL IL197450A patent/IL197450A0/en unknown
-
2013
- 2013-01-30 JP JP2013015294A patent/JP2013128487A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
RU2009114745A (ru) | 2010-10-27 |
EP2074226A2 (en) | 2009-07-01 |
US20100004253A1 (en) | 2010-01-07 |
WO2008082730A3 (en) | 2009-01-08 |
JP2010504530A (ja) | 2010-02-12 |
SG174826A1 (en) | 2011-10-28 |
KR20090071603A (ko) | 2009-07-01 |
JP2013128487A (ja) | 2013-07-04 |
WO2008082730A2 (en) | 2008-07-10 |
IL197450A0 (en) | 2009-12-24 |
AU2007340265B2 (en) | 2012-07-26 |
BRPI0716944A2 (pt) | 2013-09-17 |
CN101541977A (zh) | 2009-09-23 |
CA2662508A1 (en) | 2008-07-10 |
AU2007340265A1 (en) | 2008-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009002936A (es) | Biomarcadores de la modulacion de objetivo, eficacia, diagnostico, y/o pronostico para los inhibidores de raf. | |
WO2007067968A3 (en) | Effects of inhibitors of fgfr3 on gene transcription | |
TW200639163A (en) | RAF inhibitor compounds and methods | |
WO2008073919A3 (en) | Mir-20 regulated genes and pathways as targets for therapeutic intervention | |
WO2011090738A3 (en) | Type ii raf kinase inhibitors | |
WO2007081740A3 (en) | Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers | |
MX2012009030A (es) | Identificacion de mutacion lkb1 como biomarcador predictivo para sensibilidad a inhibidores de tor cinasa. | |
UA101478C2 (ru) | Соединения, полезные как ингибиторы raf-киназы | |
WO2010031056A3 (en) | Methods and compositions for modulating ire1, src, and abl activity | |
MY172372A (en) | Compositions and methods for lowering triglycerides | |
WO2012045905A3 (es) | Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama | |
WO2009126310A3 (en) | Methods for identification and use of agents targeting cancer stem cells | |
WO2013182912A3 (en) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis | |
MX2009012625A (es) | Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21. | |
MX2018008169A (es) | Tratamiento de tumores que incorpora isocitrato deshidrogenasa mutante. | |
MX2014001246A (es) | Identificación del perfil de la expresión génica como biomarcador predictivo del estatus de lkb1. | |
EA201200793A1 (ru) | Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин | |
WO2008036741A3 (en) | Mir-200 regulated genes and pathways as targets for therapeutic intervention | |
WO2011088137A3 (en) | Bad pathway gene signature | |
WO2014057357A3 (en) | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf | |
WO2009092108A3 (en) | Biomarkers for the diagnosis and treatment of pancreatic cancer | |
MX2010005768A (es) | Composiciones y métodos para inhibir la activación del arnbc-dependiente de la proteina de la kinasa y la inhibición del crecimiento tumoral. | |
ATE534738T1 (de) | Mir-126-regulierte gene und pfade als ziele für therapeutische interventionen | |
WO2009055823A3 (en) | Method to predict responsiveness of breast cancer to polyaminetype chemotherapy | |
WO2013083098A3 (en) | Method of determination of cancer cell drug sensitivity towards aurora kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HH | Correction or change in general | ||
FG | Grant or registration |